Quadria Capital-Led Group Seeks Majority Control of Samarth Lifesciences at INR 4,500 Cr

The deal remains under review, with multiple private equity firms assessing the chance to secure a controlling stake in the Mumbai-based pharmaceutical firm, known for its robust footprint in critical care therapies.

A consortium of private equity investors, led by healthcare specialist Quadria Capital, is evaluating the purchase of an 80-85% stake in Samarth Lifesciences. The potential deal could value the company at approximately Rs 4,500 crore, as promoters seek funds to fuel expansion and operational scaling.

The deal remains under review, with multiple private equity firms assessing their chances of securing a controlling stake in the Mumbai-based pharmaceutical firm, known for its robust footprint in critical care therapies.

As per reports, post-transaction, promoters will retain a minority stake of roughly 15-20%, enabling continued involvement in the company's growth. O3 Capital has been engaged as the advisor overseeing the deal process.

Founded in 1963, Samarth Lifesciences has built a diversified portfolio across key therapeutic segments, including critical care, cardiology, anti-infectives, urology, oncology, and gynaecology.

After remaining relatively under the radar for years, the company has gained investor interest due to better financial results. It is expected to have revenues of about ₹727 crore, growing at around 16%, with EBITDA between ₹160–170 crore for FY26.

Earlier, global investors like EQT, TPG, KKR, and Warburg Pincus looked into the deal but pulled out due to disagreements over valuation with the promoters.

Quadria Capital, based in Singapore, manages over $4.2 billion in assets. It has been investing in healthcare companies across South and Southeast Asia, including several pharma firms in India.

Stay tuned for more such updates on Digital Health News